1Medical Toxicology 2Department of Internal Medicine 3Department of Emergency Medicine, San Antonio Military Medical Center, San Antonio, TX.
Am J Ther. 2014 May-Jun;21(3):e82-4. doi: 10.1097/MJT.0b013e31824714a8.
Liver function test (LFT) increase is an early sign of acetaminophen (APAP) toxicity. Typically, when an acute overdose patient is evaluated and has an initial undetectable APAP level and normal liver enzymes, the patient is not treated with N-acetylcysteine, and liver enzymes are not expected to increase later. We report a case of moderate LFT increase despite normal LFTs and an undetectable APAP level after delayed presentation of an APAP ingestion. A 22-year-old male with no medical history ingested 15-25 hydrocodone/APAP tablets (5 mg/500 mg). His suicide note and his bunkmate corroborated the overdose time. He arrived at the emergency department 16 hours after ingestion. At that time, his APAP level was <10 μg/mL, and his liver enzymes were normal [aspartate transaminase (AST) 31 U/L and alanine transaminase (ALT) 34 U/L]. Twenty-nine hours after ingestion, the psychiatry team obtained LFTs (AST 45, ALT 61). He had persistent nausea and diffuse abdominal pain. On repeat analysis, the APAP level at 36 hours was found to be <10 μg/mL, AST 150, and ALT 204. After 2 more days of increasing LFTs and persistent abdominal pain and nausea, the toxicology department was consulted, the patient was transferred to the medicine department, and intravenous N-acetylcysteine was started 66 hours after ingestion. He was treated for 16 hours and had a significant decline in LFTs and symptom resolution. His prothrombin time, bilirubin, lactate, creatinine, and mental status were normal throughout the admission. Other cases of LFT increase were excluded. Our case report illustrates that a moderate increase in liver transaminase may occur despite an initial undetectable APAP level and normal transaminases after a delayed presentation. In our case, no serious clinical effects were reported.
肝功能检查(LFT)升高是乙酰氨基酚(APAP)毒性的早期迹象。通常,当评估急性过量患者且初始 APAP 水平无法检测且肝酶正常时,患者无需接受 N-乙酰半胱氨酸治疗,并且预计稍后肝酶不会升高。我们报告了一例在延迟出现 APAP 摄入后,尽管 LFT 正常且 APAP 水平无法检测,但 LFT 仍中度升高的病例。一名 22 岁男性,无既往病史,摄入了 15-25 片氢可酮/APAP 片剂(5 毫克/500 毫克)。他的自杀遗书和他的同屋室友证实了服药过量的时间。他在摄入后 16 小时到达急诊部。当时,他的 APAP 水平<10μg/mL,肝酶正常[天门冬氨酸转氨酶(AST)31U/L,丙氨酸转氨酶(ALT)34U/L]。摄入后 29 小时,精神科团队获得了肝功能检查(AST 45,ALT 61)。他持续恶心并出现弥漫性腹痛。重复分析发现,36 小时时 APAP 水平<10μg/mL,AST 150,ALT 204。在又 2 天 LFT 持续升高和持续腹痛和恶心后,咨询了毒理学部门,将患者转至内科,并在摄入后 66 小时开始静脉注射 N-乙酰半胱氨酸。他接受了 16 小时的治疗,LFT 明显下降,症状缓解。整个住院期间,他的凝血酶原时间、胆红素、乳酸、肌酐和精神状态均正常。排除了其他 LFT 升高的病例。我们的病例报告表明,在延迟出现的情况下,尽管初始 APAP 水平无法检测且转氨酶正常,仍可能出现中等程度的肝转氨酶升高。在我们的病例中,没有报告严重的临床影响。